Breast最新文献

{"title":"Nationwide real-world practice pattern and clinical data of palbociclib in HR (+), HER2 (−) metastatic breast cancer patients in Korea (KCSG BR21-15)","authors":"Jieun Lee ,&nbsp;Dae-Won Lee ,&nbsp;Min Hwan Kim ,&nbsp;Jee Hung Kim ,&nbsp;Ju Won Kim ,&nbsp;Jae-Ho Byun ,&nbsp;Kyoung Eun Lee ,&nbsp;Myoung Joo Kang ,&nbsp;Su-Jin Koh ,&nbsp;Soojung Hong ,&nbsp;Hye Sung Won ,&nbsp;Han Jo Kim ,&nbsp;In Hae Park ,&nbsp;Seong Hoon Shin ,&nbsp;Sun Kyung Baek ,&nbsp;Seul-Gi Kim ,&nbsp;Sung Ae Koh ,&nbsp;Joo Young Jung ,&nbsp;Ji-Yeon Kim ,&nbsp;Gun Min Kim ,&nbsp;Yeon Hee Park","doi":"10.1016/j.breast.2025.104500","DOIUrl":"10.1016/j.breast.2025.104500","url":null,"abstract":"<div><h3>Background</h3><div>Cyclin-dependent kinase (CDK) 4/6 inhibitors have remarkably improved the survival outcome in hormone-receptor-positive (HR+)/human epidermal growth factor-2-negative (HER2-) metastatic breast cancer (mBC). Although PALOMA-2 has met its primary outcome, overall survival (OS) was relatively shorter compared to ribociclib and abemaciclib. In Korea, use of palbociclib + aromatase inhibitor (AI) + gonadotropin-releasing hormone agonist (GnRHa) in premenopausal women is limited, and bilateral salpingo-oophorectomy (BSO) is necessary before treatment. We analyzed the real-world clinical outcome and patient characteristics of letrozole + palbociclib in Korea.</div></div><div><h3>Methods</h3><div>Between August 2016 and December 2022, 1017 HR+/HER2-postmenopausal women treated with first-line letrozole + palbociclib were enrolled. Primary endpoints were real-world progression-free survival (rwPFS) in total population and survival differences according to menopausal status (natural or induced menopause via BSO).</div></div><div><h3>Results</h3><div>Patients’ median age was 56 (range 27–92) years. Median rwPFS, real-world OS (rwOS) were 28.0 months (95 % confidence interval [CI] 25.5–32.1) and 61.8 months (95 % CI 57.7–70.5), with a median follow-up of 45.1 (IQR, 31.0–56.6) months. BSO group demonstrated similar median rwPFS compared to natural menopause group. Adjuvant tamoxifen ± GnRHa was most frequently prescribed (73.3 %). Primary endocrine resistant mBC patients showed inferior median rwPFS compared to secondary resistant mBC (14.6 vs. 27.1 months, <em>p</em> = 0.0063). Overall response rate was 47.5 %, with a disease control rate of 89.6 %.</div></div><div><h3>Conclusion</h3><div>This is the largest country-based real-world study on palbociclib + letrozole in Asia. Palbociclib demonstrated median rwOS over 60 months, comparable to other pivotal trials.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"82 ","pages":"Article 104500"},"PeriodicalIF":5.7,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144072132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing breast cancer therapy in the era of molecular diagnostics","authors":"Maria Grazia Carnevale ,&nbsp;Riccardo Ray Colciago ,&nbsp;Maria Carmen De Santis ,&nbsp;Laura Cortesi ,&nbsp;Cinzia De Marco ,&nbsp;Antonio Marra ,&nbsp;Andrea Vingiani ,&nbsp;Franco Nolè ,&nbsp;Giuseppe Curigliano ,&nbsp;Giancarlo Pruneri ,&nbsp;Antonio Llombart-Cussac ,&nbsp;Serena Di Cosimo ,&nbsp;Javier Cortes","doi":"10.1016/j.breast.2025.104488","DOIUrl":"10.1016/j.breast.2025.104488","url":null,"abstract":"<div><div>Advances in cancer biology and drug development now enable treatments tailored to individual tumor profile. Targeting specific molecular alterations marked a significant step forward in cancer care, including breast cancer. Access to these therapies is improving thanks to the implementation of molecular tumor boards and efforts to provide molecular diagnostics at sustainable costs for all. In this context, we highlight recent progress in breast cancer therapy, focusing on biomarker-driven approaches, immunotherapy, and precision medicine paving the way for increasingly personalized and effective options.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"82 ","pages":"Article 104488"},"PeriodicalIF":5.7,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple dimensions of the quality of life among Asian American breast cancer survivors: The impact of a technology-based program","authors":"Eun-Ok Im ,&nbsp;Wonshik Chee ,&nbsp;Sudeshna Paul ,&nbsp;Seo Yun Kim ,&nbsp;Mi-Young Choi ,&nbsp;Jun J. Mao ,&nbsp;Giang T. Nguyen ,&nbsp;Marilyn M. Schapira ,&nbsp;Connie M. Ulrich ,&nbsp;SeonAe Yeo ,&nbsp;Janet A. Deatrick ,&nbsp;Jillian Inouye ,&nbsp;Grace Ma ,&nbsp;Salimah Meghani ,&nbsp;David Shin ,&nbsp;Ting Bao","doi":"10.1016/j.breast.2025.104490","DOIUrl":"10.1016/j.breast.2025.104490","url":null,"abstract":"<div><h3>Objective</h3><div>The purpose of this study was to examine if a technology-based information and coaching/support program could improve the quality of life of Asian American breast cancer survivors and determine the factors that influenced the changes in the women's quality of life by the technology-based program.</div></div><div><h3>Methods</h3><div>This was a randomized controlled trial with 199 Asian American breast cancer survivors (104 in the intervention group and 95 in the control group). Multiple instruments including the Functional Assessment of Cancer Therapy Scale-Breast Cancer (FACT-B) were used to assess background factors, disease factors, and the quality of life. The data were analyzed using intent-to-treat general linear models.</div></div><div><h3>Results</h3><div>The FACT-B total and subscale scores of the intervention group increased from pre-test (T0) to post 3-months (T2), while those of the control group decreased. Significant interaction between time and group were found only in physical well-being (<em>β</em> = 0.84, <em>p</em> = .025) from T0 to T1 (post 1-month) and social well-being (<em>β</em> = 1.05, <em>p</em> = .006) from T0 to T2 within the mixed-effect model with AR1. The PRQ scores mediated the effect of the technology-based intervention on the Breast Cancer Subscale scores (<em>p</em> &lt; .05) over one month (T0 to T1).</div></div><div><h3>Conclusion</h3><div>The technology-based program improved physical and social well-being among Asian American breast cancer survivors. Social support mediated the impact of the program on the quality of life. Future studies are needed on different dimensions of the quality of life with diverse groups of survivors. NCT02803593.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"82 ","pages":"Article 104490"},"PeriodicalIF":5.7,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143934851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimization of guidelines for Risk Of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study","authors":"Una Kjällquist ,&nbsp;Nikos Tsiknakis ,&nbsp;Balazs Acs ,&nbsp;Sara Margolin ,&nbsp;Luisa Edman Kessler ,&nbsp;Scarlett Levy ,&nbsp;Maria Ekholm ,&nbsp;Christine Lundgren ,&nbsp;Erik Olsson ,&nbsp;Henrik Lindman ,&nbsp;Antonios Valachis ,&nbsp;Johan Hartman ,&nbsp;Theodoros Foukakis ,&nbsp;Alexios Matikas","doi":"10.1016/j.breast.2025.104489","DOIUrl":"10.1016/j.breast.2025.104489","url":null,"abstract":"<div><h3>Purpose</h3><div>Gene expression profiles are used for decision making in the adjuvant setting in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. While algorithms to optimize testing exist for RS/Oncotype Dx, no such efforts have focused on ROR/Prosigna. This study aims to enhance pre-selection of patients for testing using machine learning.</div></div><div><h3>Methods</h3><div>We included 348 postmenopausal women with resected HR+/HER2-node-negative breast cancer tested with ROR/Prosigna across four Swedish regions. We developed a machine learning model using simple prognostic factors (size, progesterone receptor expression, grade, and Ki67) to predict ROR/Prosigna output and compared the performance regarding over- and undertreatment with commonly employed risk stratification schemes.</div></div><div><h3>Results</h3><div>Previous classifications resulted in significant undertreatment or large intermediate groups needing gene expression profiling. The machine learning model achieved AUC under ROC of 0.77 in training and 0.83 in validation cohorts for prediction of indication for adjuvant chemotherapy according to ROR/Prosigna. By setting and validating upper and lower cut-offs corresponding to low, intermediate and high-risk disease, we improved risk stratification accuracy and reduced the proportion of patients needing ROR/Prosigna testing compared to current risk stratification.</div></div><div><h3>Conclusion</h3><div>Machine learning algorithms can enhance patient selection for gene expression profiling, though further external validation is needed.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"82 ","pages":"Article 104489"},"PeriodicalIF":5.7,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143929160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phyllodes tumors of the breast: Real world data from a multi-institution cohort","authors":"Carl Sars ,&nbsp;Jan Frisell ,&nbsp;Paul W. Dickman ,&nbsp;Felix Haglund de Flon ,&nbsp;Fredrik Karlsson ,&nbsp;Helena Sackey ,&nbsp;Ebba K. Lindqvist","doi":"10.1016/j.breast.2025.104491","DOIUrl":"10.1016/j.breast.2025.104491","url":null,"abstract":"<div><h3>Introduction</h3><div>Phyllodes tumors (PT) are rare breast lesions arising from fibroepithelial stroma and may be hard to clinically distinguish from fibroadenomas. They are defined as benign, borderline or malignant. The purpose of this study was to describe diagnostic workup and surgical management, and to investigate incidence of local recurrence (LR) and overall survival (OS) in relation to tumor subtype, size, age, surgical margins, surgical method, and year of diagnosis.</div></div><div><h3>Methods</h3><div>Retrospective cohort study of all patients surgically treated for a PT in Stockholm, Sweden from 1999 to 2018. Descriptive analyses were performed, and regression models were used to analyze associations between selected covariates and LR and OS.</div></div><div><h3>Results</h3><div>Among 191 patients, 132 were treated for a benign PT, 40 for a borderline PT and 19 for a malignant PT. Preoperatively, results from diagnostic workup were often ambiguous, and only 45.6 % of cases had a preoperative diagnosis of PT. Initial surgery was breast-conserving in 93.2 % of patients. Recurrences occurred in 10.5 % of the total cohort. 5-year and 10-year OS was 96.1 % and 93.5 %, respectively, for the entire cohort. In a multivariable analysis, neither covariate was associated with risk of LR. Distant recurrences were only detected among patients with malignant PT.</div></div><div><h3>Conclusions</h3><div>In the workup of PT, common diagnostic methods such as FNAC, CNB, and mammography may be unreliable, and clinical suspicion plays a critical role in guiding pre-operative decision-making. We found no association between surgical margins and rate of LR or OS. We found no evidence of metastatic potential in benign or borderline PT.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"82 ","pages":"Article 104491"},"PeriodicalIF":5.7,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143922519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the efficacy of extended endocrine therapy in pure mucinous breast carcinoma","authors":"Young-Won Lee ,&nbsp;Sae-Byul Lee ,&nbsp;Il Yong Chung ,&nbsp;Jisun Kim ,&nbsp;Hee Jeong Kim ,&nbsp;Beom Seok Ko ,&nbsp;Byung Ho Son ,&nbsp;Jong Won Lee ,&nbsp;Tae-Kyung Robyn Yoo","doi":"10.1016/j.breast.2025.104492","DOIUrl":"10.1016/j.breast.2025.104492","url":null,"abstract":"<div><h3>Background</h3><div>This study aims to compare the efficacy of 5- versus 10-year endocrine therapy in pure mucinous breast carcinoma (PMBC), focusing on late recurrence and related factors for personalized treatment.</div></div><div><h3>Methods</h3><div>Patients with PMBC who underwent surgery from 1996 to 2014 at Asan Medical Center were included. Recurrence was categorized as early (&lt;5 years) or late (≥5 years). The primary endpoint was disease-free survival in the 5- and 10- year endocrine groups. Subgroup analysis was performed focused on clinically high-risk patients (tumor ≥2 cm, nodal metastasis, or high histologic grade).</div></div><div><h3>Results</h3><div>A total of 489 patients with PMBC were identified. During a follow-up time of 126 months, 35 (7.2 %) patients had an early recurrence, 25 (5.1 %) patients had a late recurrence, and 394 (87.7 %) patients had no recurrence. High histologic grade was the only factor significantly correlated to late recurrence (hazard ratio 6.92, 95 % confidence interval 1.53–31.3). Among the 5-year disease-free survivors (N = 416), 340 (81.7 %) and 76 (18.3 %) patients underwent 5-year and 10-year endocrine therapy, respectively. Endocrine therapy duration did not impact the 10-year disease-free survival rate (5-year [95.4 %] vs. 10-year [97.3 %] endocrine therapy, log-rank test p = 0.504). Subgroup analysis with clinically high-risk patients revealed no survival difference based on the endocrine therapy duration, too.</div></div><div><h3>Conclusion</h3><div>Extended endocrine therapy did not significantly reduce late recurrence in PMBC, even in high-risk groups, underscoring the importance of personalized strategies for sustained outcomes.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"82 ","pages":"Article 104492"},"PeriodicalIF":5.7,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143929159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in the global, national, and regional burden of breast cancer among adolescents and young adults from 1990 to 2021: Analyses of the 2021 global burden of disease study","authors":"Da Qian ,&nbsp;Weimin Hong ,&nbsp;Shujin Li ,&nbsp;Haotian Liu ,&nbsp;Chaoqi He ,&nbsp;Xiaozhen Liu ,&nbsp;Guoxin Huang ,&nbsp;Xuli Meng ,&nbsp;Yiwen Zheng","doi":"10.1016/j.breast.2025.104486","DOIUrl":"10.1016/j.breast.2025.104486","url":null,"abstract":"<div><h3>Background</h3><div>This study was devised to evaluate the burden of breast cancer (BC) among adolescents and young adults (AYAs) between 1990 and 2021.</div></div><div><h3>Methods</h3><div>BC burden among AYAs (15–39 years of age) was analyzed by examining the associated age-standardized incidence rate, age-standardized prevalence rate, age-standardized death rate, and age-standardized disability-adjusted life year (DALY) rates between 1990 and 2021 at the global, national, and regional levels, together with corresponding analyses of health inequality and decomposition analyses.</div></div><div><h3>Results</h3><div>In 2021, the respective global age-standardized incidence rate, age-standardized prevalence rate, age-standardized death rate, and age-standardized DALYs for BC were 5.87 (5.39,6.41), 49.35 (45.46,53.86), 1.37 (1.24,1.51), and 80.8 (72.84,89.23), which respectively showed increases of 33.4 %, 35.2 %, 1.5 %, and 3.3 % compared to the rate of 1990. While women comprise the vast majority of all BC cases, a higher average annual percent change was observed for males relative to females at the global level. The average annual percent change for BC incidence, prevalence, death, and DALYs among men AYAs (2.59, 2.49, 1.06, 1.10) were all higher than the corresponding values among women (0.91, 0.96, 0.02, 0.09). Regional and national differences in disease burden were observed. BC disease burden was significantly positively correlated with socio-demographic index (SDI). Similar trends were observed in terms of female disease burden, whereas disease burden of male patients was negatively related to SDI. In decomposition analyses, the primary factors associated with changes in age-standardized DALY rates were identified as aging and population growth. Health inequality analyses revealed that the burden of BC among AYAs was particularly concentrated in lower-income countries.</div></div><div><h3>Conclusions</h3><div>These results highlight that the burden of BC among AYAs has grown in recent decades, while also emphasizing the need to be attentive to the rising occurrence of male BC. Lower-income regions also faced a heavier BC-related burden as compared to more affluent nations. Efforts to reduce the disease burden associated with BC may thus hinge on government-based initiatives focused on improving overall national economic strength and medical system quality.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"82 ","pages":"Article 104486"},"PeriodicalIF":5.7,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143922520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists","authors":"Hope S. Rugo ,&nbsp;Aditya Bardia ,&nbsp;William J. Gradishar ,&nbsp;Erika P. Hamilton ,&nbsp;Sara A. Hurvitz ,&nbsp;Komal Jhaveri ,&nbsp;Reshma Mahtani ,&nbsp;Sara M. Tolaney","doi":"10.1016/j.breast.2025.104485","DOIUrl":"10.1016/j.breast.2025.104485","url":null,"abstract":"<div><div>Hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2-mBC) is incurable, but recent progress has been made in developing new treatment options and the treatment landscape is rapidly shifting. There are published recommendations for treatment choices and sequencing to help guide oncologists in treating HR+/HER2-mBC, but little evidence has been published regarding real-world practice patterns. The REal-world TReatment patterns And Considerations of Toxicity in HR+/HER2-mBC (RETRACT) survey was designed to evaluate real-world practice patterns in the testing and management of this disease by US oncologists. The survey questions were answered via an online platform and the data were anonymized before analysis. A total of 150 oncologists practicing at academic and community centers completed the survey. The results showed this sample of oncologists largely followed recommended best practices for testing biomarkers, selecting treatments, and managing adverse events. However, several items did show substantial minorities of oncologists not in alignment with recommendations in areas including the definition and treatment of visceral crisis, ideal treatment for patients with endocrine resistance, the routine use of next-generation sequencing for biomarker testing, and the use of prophylactic measures for treatment-related adverse events in patients receiving alpelisib.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"82 ","pages":"Article 104485"},"PeriodicalIF":5.7,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143916784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis of Breast Cancer in European female adolescents and young adults (AYAs): EUROCARE-6 retrospective cohort results","authors":"Alice Bernasconi ,&nbsp;Angela Toss ,&nbsp;Emma Zattarin ,&nbsp;Seyed Mohsen Mousavi ,&nbsp;Marcel Blum ,&nbsp;Claudia E. Kuehni ,&nbsp;Alexander Katalinic ,&nbsp;Jan Trallero ,&nbsp;Elisabetta Rapiti ,&nbsp;Luigino Dal Maso ,&nbsp;Laura Botta ,&nbsp;Silvia Rossi ,&nbsp;Fedro Peccatori ,&nbsp;Annalisa Trama ,&nbsp;the EUROCARE-6 Working Group","doi":"10.1016/j.breast.2025.104472","DOIUrl":"10.1016/j.breast.2025.104472","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer (BC) is the most common malignancy in AYA (15–39 years) females and is more aggressive than in adult women (40–69 years). However, an updated overview on BC in AYAs and how it differs from BC in adult women is lacking.</div></div><div><h3>Methods</h3><div>We used data from the EUROCARE-6 study to calculate incidence rates (IRs) of BC in AYA and adult women over the period 2001–2013 in Europe. We estimated 5-year and 10-year relative survival (RS) using period analysis. Stage at diagnosis distribution and conditional RS (CS) were used to investigate survival differences. We also reported cumulative incidence of multiple primary neoplasms (MPNs) in AYAs.</div></div><div><h3>Results</h3><div>The IR of BC in Europe was ∼18 per 100,000 in AYA females and more than ten-fold higher in adult women. Most BC cases were diagnosed at Stages I-II (74 % in AYAs vs 77 % in adults). Overall, AYAs had lower 5-year RS than adult women (85.0 % vs 89.5 %, respectively); the survival gap slightly decreased in CS. AYAs had worse survival than adult women for early stage and Stage III but better RS for Stage IV (5-year RS 31.5 % vs. 26.3 %). Cumulative incidence of all MPNs in AYAs was ∼6 % at 14 years from BC diagnosis.</div></div><div><h3>Conclusions</h3><div>Our findings support the more aggressive behavior of BC in AYAs. The high proportion of early stage at diagnosis is reassuring considering that organized BC screening is not available for AYAs in Europe. Conversely, the incidence of MPNs in AYAs is relevant and might deserve a revision of follow-up strategies.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"82 ","pages":"Article 104472"},"PeriodicalIF":5.7,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144138024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A population-based estimation of breast cancer recurrence in northeast Italy with administrative healthcare databases","authors":"Fabiola Giudici ,&nbsp;Federica Toffolutti ,&nbsp;Stefano Guzzinati ,&nbsp;Francesco Schettini ,&nbsp;Marina Bortul ,&nbsp;Silvia Francisci ,&nbsp;Manuel Zorzi ,&nbsp;Sara De Vidi ,&nbsp;Daniela Pierannunzio ,&nbsp;Luigino Dal Maso","doi":"10.1016/j.breast.2025.104487","DOIUrl":"10.1016/j.breast.2025.104487","url":null,"abstract":"<div><h3>Background/Aim</h3><div>Information on the long-term frequency of recurrence is of paramount importance for the increasing number of women living several years after breast cancer (BC) diagnosis and for their caregivers.</div><div>The study aims to estimate the cumulative incidence of recurrence until 10 years after diagnosis in Italian women diagnosed with BC using population-based cancer registries.</div></div><div><h3>Methods</h3><div>Women diagnosed with stage I to III BC during 2004–2010 from Friuli Venezia Giulia and Veneto (Italy) cancer registries were included (n = 5825). Recurrence status after a disease-free period was ascertained through individual-level linked databases using treatment or procedure codes from claims. Cumulative incidence of recurrence was calculated in the presence of competing risks (second cancer or death).</div></div><div><h3>Results</h3><div>During a median follow-up of 13.5 years, 1522 out of 5825 women experienced a recurrence with an estimated 10-years cumulative incidence of 20.8 % (95 %CI:19.7–21.8 %), decreasing from 23.7 % in 2004–2006 to 18.5 % in 2007–2010. Women younger than 40 years (40.5 %), with stage III (41.8 %) and triple-negative BC (32.5 %) showed a higher 10-year incidence of recurrence.</div><div>At 10 years after a BC diagnosis, 83.9 % of women were alive: 67.5 % without any cancer-related events, 12.4 % after recurrence and 4.0 % after second primary cancer. 10-years survival was higher than 90 % for women with stage I BC and 58.1 % for those with stage III (3.2 % and 27.3 % deaths after recurrence, respectively).</div></div><div><h3>Discussion</h3><div>This Italian study provide detailed population-based information on the incidence of recurrence and other outcomes after BC and may be replicated in other Italian and European areas.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"82 ","pages":"Article 104487"},"PeriodicalIF":5.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143911729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}